GSK3B and acute myeloid leukemia: Since inhibition of GSK3β, a known dinaciclib target, may block Wnt signaling in the setting of constitutive activation [46], which is present in AML cells, we hypothesized that inhibition of Wnt signaling, a known BETi resistance mechanism [16, 17], may contribute to the observed combination activity.